Valneva SE Faces Investigation Over Vaccine-Related Claims

Author: Kelly Martin Updated: 09-13-2025 01:54 PM

Valneva SE Under Investigation for Potential Investor Claims

Pomerantz LLP is currently exploring legal claims on behalf of investors in Valneva SE. This investigation has arisen due to potential allegations regarding securities fraud or other unlawful activities conducted by Valneva and its leadership. Investors who feel affected are encouraged to understand their rights and may reach out for further guidance.

Concerns About Vaccine Safety

In a recent announcement, the U.S. Centers for Disease Control and Prevention (CDC) issued a notice about investigations into serious adverse events. This included reports of five hospitalizations for cardiac or neurologic issues linked to the IXCHIQ vaccine, which Valneva has developed for chikungunya virus. The situation raised concerns amongst investors and the general public, prompting an investigation into the implications of this news.

Impact on Valneva's Stock Performance

Following the CDC's findings, Valneva's American Depositary Receipt (ADR) experienced a notable decline. Within four trading sessions after the announcement, the stock price plummeted by 13.57%, closing at $6.75 per ADR. This dip is a significant concern for investors who may have seen their investments negatively impacted.

Regulatory Developments

In addition, the U.S. Food and Drug Administration (FDA) announced a suspension of the marketing application for IXCHIQ due to the identified safety concerns surrounding it. The market reacted swiftly, with Valneva's ADR dropping by 18.99% in a single day—a clear sign of investor anxiety over regulatory scrutiny and its implications for future sales and company performance. The ADR closed at $9.43 per unit shortly after this announcement.

Pomerantz LLP’s Commitment to Investor Rights

Pomerantz LLP has a longstanding reputation in handling corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, whose legacy in the field is well-respected, the firm operates with a mission to advocate fiercely for victims of securities fraud and corporate misconduct. With over 85 years of experience, Pomerantz continues to represent the interests of class members while fighting against breaches of fiduciary duty.

Investors’ Options and Resources

Those who are part of the affected investor group should consider carefully their options and seek assistance to understand their rights. If you believe you have been impacted by Valneva's practices, now may be the time to take action. Collectively, investors are encouraged to stay informed about any developments regarding the investigation and evaluate their positions in the company.

Frequently Asked Questions

What is the current status of the investigation into Valneva SE?

Pomerantz LLP is investigating claims that may connect Valneva to securities fraud or unlawful practices affecting investors.

How has Valneva's stock reacted to recent news?

Valneva's ADR fell significantly following CDC and FDA announcements regarding safety concerns surrounding its vaccine.

What are the implications of the FDA's suspension of IXCHIQ?

The suspension indicates serious safety concerns, potentially affecting future sales and investor confidence.

How can affected investors seek assistance?

Affected investors can reach out to Pomerantz LLP for support and guidance about their rights in pursuing claims.

What is the historical significance of Pomerantz LLP?

Pomerantz has a rich history in defending investor rights, having pioneered securities class action lawsuits over 85 years ago.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.